Global Dynamic Blood Glucose Monitoring Device Market Growth 2025-2031
Description
The global Dynamic Blood Glucose Monitoring Device market size is predicted to grow from US$ 2822 million in 2025 to US$ 4904 million in 2031; it is expected to grow at a CAGR of 9.6% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Dynamic blood glucose monitoring refers to the technology of continuously monitoring the glucose concentration in subcutaneous interstitial fluid through glucose sensors. Simply put, a coin sized sensor is worn on the abdomen or back of the upper arm. The sensor measures and records blood glucose data every 5 minutes, providing continuous, comprehensive, and accurate 24-hour blood glucose information, understanding the trend of blood glucose changes, and making high and low blood glucose have nowhere to hide. As one of the "five carriages" of diabetes management, blood glucose monitoring plays a vital role in the diagnosis, treatment and follow-up of diabetes patients. Blood glucose monitoring includes traditional self-monitoring, glycated albumin, glycated hemoglobin, and other invasive blood collection methods, which make it difficult for many patients to adhere to in the long term. In recent years, continuous glucose monitoring (commonly referred to as dynamic blood glucose monitoring in clinical practice) technology has become an effective supplement to traditional blood glucose monitoring methods, making blood glucose monitoring easy and painless, and gradually being promoted and applied in clinical practice.
Diabetes is a systemic disease caused by the interaction of genetic and environmental factors, resulting in insufficient insulin secretion, defective insulin action, or the simultaneous existence of both. "Three more and one less", that is, the clinical manifestations of "drinking more, urinating more, eating more and losing weight", are more common in type I diabetes, and patients with type I diabetes need lifelong insulin treatment; fatigue, weakness and obesity are more common in type II diabetes, and intensive insulin treatment has better therapeutic effects on patients with type II diabetes who have severely insufficient insulin secretion. The latest blood sugar is the only criterion for diagnosing diabetes. The World Health Organization's diagnostic criteria for diabetes are: fasting (no calories for at least 8 hours) blood sugar level ≥7 mmol/L, or diabetes symptoms + plasma glucose level ≥11.1 mmol/L at any time. my country is a high-incidence area of diabetes, and 141 million diabetic patients have released strong demand for blood sugar monitoring. As patient needs evolve, the importance of CGM is becoming increasingly prominent. There is a lot of room for improvement in the domestic CGM market penetration rate and domestic production rate.
LP Information, Inc. (LPI) ' newest research report, the “Dynamic Blood Glucose Monitoring Device Industry Forecast” looks at past sales and reviews total world Dynamic Blood Glucose Monitoring Device sales in 2024, providing a comprehensive analysis by region and market sector of projected Dynamic Blood Glucose Monitoring Device sales for 2025 through 2031. With Dynamic Blood Glucose Monitoring Device sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dynamic Blood Glucose Monitoring Device industry.
This Insight Report provides a comprehensive analysis of the global Dynamic Blood Glucose Monitoring Device landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dynamic Blood Glucose Monitoring Device portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dynamic Blood Glucose Monitoring Device market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dynamic Blood Glucose Monitoring Device and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dynamic Blood Glucose Monitoring Device.
This report presents a comprehensive overview, market shares, and growth opportunities of Dynamic Blood Glucose Monitoring Device market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Wearable
Implant
Segmentation by Application:
Hospital Use
Home Use
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Abbott
DexCom
Medtronic
Senseonics Holdings
Glucotrack, Inc.
Medtrum Technologies
Roche
I-SENS
AgaMatrix
Sinocare
Huzhou Meiqi Medical Instruments
Zhejiang POCTech Corporation
MicroTech Medical
SIBIONICS
Key Questions Addressed in this Report
What is the 10-year outlook for the global Dynamic Blood Glucose Monitoring Device market?
What factors are driving Dynamic Blood Glucose Monitoring Device market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dynamic Blood Glucose Monitoring Device market opportunities vary by end market size?
How does Dynamic Blood Glucose Monitoring Device break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Dynamic blood glucose monitoring refers to the technology of continuously monitoring the glucose concentration in subcutaneous interstitial fluid through glucose sensors. Simply put, a coin sized sensor is worn on the abdomen or back of the upper arm. The sensor measures and records blood glucose data every 5 minutes, providing continuous, comprehensive, and accurate 24-hour blood glucose information, understanding the trend of blood glucose changes, and making high and low blood glucose have nowhere to hide. As one of the "five carriages" of diabetes management, blood glucose monitoring plays a vital role in the diagnosis, treatment and follow-up of diabetes patients. Blood glucose monitoring includes traditional self-monitoring, glycated albumin, glycated hemoglobin, and other invasive blood collection methods, which make it difficult for many patients to adhere to in the long term. In recent years, continuous glucose monitoring (commonly referred to as dynamic blood glucose monitoring in clinical practice) technology has become an effective supplement to traditional blood glucose monitoring methods, making blood glucose monitoring easy and painless, and gradually being promoted and applied in clinical practice.
Diabetes is a systemic disease caused by the interaction of genetic and environmental factors, resulting in insufficient insulin secretion, defective insulin action, or the simultaneous existence of both. "Three more and one less", that is, the clinical manifestations of "drinking more, urinating more, eating more and losing weight", are more common in type I diabetes, and patients with type I diabetes need lifelong insulin treatment; fatigue, weakness and obesity are more common in type II diabetes, and intensive insulin treatment has better therapeutic effects on patients with type II diabetes who have severely insufficient insulin secretion. The latest blood sugar is the only criterion for diagnosing diabetes. The World Health Organization's diagnostic criteria for diabetes are: fasting (no calories for at least 8 hours) blood sugar level ≥7 mmol/L, or diabetes symptoms + plasma glucose level ≥11.1 mmol/L at any time. my country is a high-incidence area of diabetes, and 141 million diabetic patients have released strong demand for blood sugar monitoring. As patient needs evolve, the importance of CGM is becoming increasingly prominent. There is a lot of room for improvement in the domestic CGM market penetration rate and domestic production rate.
LP Information, Inc. (LPI) ' newest research report, the “Dynamic Blood Glucose Monitoring Device Industry Forecast” looks at past sales and reviews total world Dynamic Blood Glucose Monitoring Device sales in 2024, providing a comprehensive analysis by region and market sector of projected Dynamic Blood Glucose Monitoring Device sales for 2025 through 2031. With Dynamic Blood Glucose Monitoring Device sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dynamic Blood Glucose Monitoring Device industry.
This Insight Report provides a comprehensive analysis of the global Dynamic Blood Glucose Monitoring Device landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dynamic Blood Glucose Monitoring Device portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dynamic Blood Glucose Monitoring Device market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dynamic Blood Glucose Monitoring Device and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dynamic Blood Glucose Monitoring Device.
This report presents a comprehensive overview, market shares, and growth opportunities of Dynamic Blood Glucose Monitoring Device market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Wearable
Implant
Segmentation by Application:
Hospital Use
Home Use
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Abbott
DexCom
Medtronic
Senseonics Holdings
Glucotrack, Inc.
Medtrum Technologies
Roche
I-SENS
AgaMatrix
Sinocare
Huzhou Meiqi Medical Instruments
Zhejiang POCTech Corporation
MicroTech Medical
SIBIONICS
Key Questions Addressed in this Report
What is the 10-year outlook for the global Dynamic Blood Glucose Monitoring Device market?
What factors are driving Dynamic Blood Glucose Monitoring Device market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dynamic Blood Glucose Monitoring Device market opportunities vary by end market size?
How does Dynamic Blood Glucose Monitoring Device break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
119 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Dynamic Blood Glucose Monitoring Device by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Dynamic Blood Glucose Monitoring Device by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
